Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06487247 · ClinicalTrials.gov registry record · NA
HEME Home Transfusion Program
A NA study of Lymphoma and Leukemia, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- NA
- Development phase
- 700
- Enrollment target
- 2
- Study locations
NCT06487247: Recruiting NA study of Lymphoma and Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT06487247 is a NA study of Lymphoma and Leukemia that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 700 participants, above the 481-participant average among 299 other Lymphoma trials with a reported enrollment target (46% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06487247, a NA study of Lymphoma and Leukemia, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- NA
- Development phase
- 700 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies.
Primary Outcome
Establish that hospice enrollment rate is higher with access to HEME-Hospice versus usual care.
Conditions Studied
Interventions
- BEHAVIORAL HEME-Hospice Program
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2025-09-10 |
| Est. Completion | 2029-05-31 |
| Phase | NA |
What NCT06487247 shows while recruiting
NCT06487247 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 481-participant average among 299 other Lymphoma trials with a reported enrollment target (46% higher).
The record links to 6 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which HEME-Hospice Program is the first listed.
NCT06487247 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06487247 about?
NCT06487247 is a clinical study titled "HEME Home Transfusion Program". This research study is evaluating whether a new care delivery program that provides access to home blood transfusions in hospice (i.e, HEME-Hospice) compared to regular standard of care improves quality of life, mood, and end-of-life health care utilization for patients with hematologic malignancies...
What is the current status of trial NCT06487247?
This trial is currently recruiting. It is a NA study. The enrollment target is 700 participants. The study started on 2025-09-10. Estimated completion is 2029-05-31.
What conditions does trial NCT06487247 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Hematologic Malignancy, Myeloma.
What interventions are being tested in trial NCT06487247?
The interventions under investigation include: HEME-Hospice Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06487247?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06487247 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06487247's enrollment target sits among peer trials
700 10th of 299 higher than 290 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI